ClinicalTrials.gg
CompletedNCT00467844Updated Jul 11, 2014Results posted

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

A Phase 2 interventional study of GTx-024 and GTx-024 in Cachexia, sponsored by GTx. Completed at 52 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by GTx · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Enrollment
15th of 72
159 · median 51
Started
2007
with 3 others
Phase 2
24 of 95
2 open now
Registered
24th of 95
by date

Among the 95 studies in Cachexia with a site in United States, this one is the 15th largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2007, is one of 24 in phase 2, and was the 24th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.

Read the detailed description

Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).

The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body fat mass.

03

Conditions studied

  • Cachexia

Keywords

  • Cachexia
  • Muscle Wasting
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Non-Hodgkin's Lymphoma
  • Stage 3 or 4 Breast Cancer
  • Chronis Lymphocytic Leukemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for participation in this study, subjects must meet all of the following criteria:

  • have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.
  • be prior to initiation of or between cycles of chemotherapy.
  • have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)

    % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%

  • If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.
  • have a of >6 months
  • FEMALES - be clinically confirmed as
  • MALES - over 45 years of age
  • score ≤1

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following will NOT be eligible for enrollment in this study:

  • history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or infection
  • Cardiovascular: No uncontrolled hypertension
  • Positive screen for consisting of HBsAg (Hepatitis B Surface Antigen), anti- (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV
  • Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate .)
  • Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    1

    1 mg GTx-024

    Drug: GTx-024

  • Experimental
    2

    3 mg GTx-024

    Drug: GTx-024

  • Placebo comparator
    3

    Placebo

    Drug: Placebo

Interventions

  • 1 mg GTx 024

  • 3 mg GTx-024

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. The Efficacy of GTx-024 on Total Body Lean Mass.

    Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.

    Time frame: Baseline to Four Months

Secondary outcomes

  1. To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.

    Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\[9.8 m/sec\*\*2\]\*\[weight (kg)\]\*\[height of 12 steps(meters)\]/ \[time (seconds) up the 12 steps\].

    Time frame: Four Months

07

Results

Posted Feb 21, 2013

Participant flow

Participant flow — Overall Study
MilestoneGTx -024GTx-0243 mg of Placebo
Started535452
Completed343438
Not completed192014

Outcome measures

PrimaryThe Efficacy of GTx-024 on Total Body Lean Mass.

Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.

Time frame:
Baseline to Four Months
Reported as:
Median · kg
The Efficacy of GTx-024 on Total Body Lean Mass.
kgGTx-024 1 mgGTx-024 3 mgPlacebo
The Efficacy of GTx-024 on Total Body Lean Mass.1.55 (-2.06 to 12.64)0.98 (-4.84 to 11.54)0.02 (-5.81 to 7.46)
SecondaryTo Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.

Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\[9.8 m/sec\*\*2\]\*\[weight (kg)\]\*\[height of 12 steps(meters)\]/ \[time (seconds) up the 12 steps\].

Time frame:
Four Months
Reported as:
Median · watts
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.
wattsGTx -024GTx-0243 mg of Placebo
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.19.93 (-235.3 to 110.1)12.84 (-77.7 to 93.1)11.34 (-156.4 to 56.4)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx -024—14/53 (26.4%)47/53 (88.7%)
GTx-024—15/54 (27.8%)49/54 (90.7%)
3 mg of Placebo—17/52 (32.7%)46/52 (88.5%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventGTx -024GTx-0243 mg of Placebo
malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/537/548/52
Febrile NeutropeniaBlood and lymphatic system disorders2/530/543/52
AnaemiaBlood and lymphatic system disorders3/530/540/52
pneumoniaInfections and infestations2/533/542/52
PancytopeniaBlood and lymphatic system disorders0/530/541/52
DysphagiaGastrointestinal disorders0/530/541/52
gastric ulcer perforationGastrointestinal disorders0/530/541/52
pancreatitisGastrointestinal disorders0/530/541/52
small intestinal obstructionGastrointestinal disorders0/530/541/52
diverticulitisInfections and infestations0/530/541/52
Most frequent other events
Showing 10 of 20
Most frequent other events
EventGTx -024GTx-0243 mg of Placebo
fatigueGastrointestinal disorders8/5314/5411/52
anaemiaBlood and lymphatic system disorders13/537/548/52
NauseaGastrointestinal disorders13/536/547/52
constipationGastrointestinal disorders9/536/542/52
vomitingGastrointestinal disorders9/534/546/52
diarrhoeaGastrointestinal disorders8/539/547/52
coughRespiratory, thoracic and mediastinal disorders2/539/546/52
malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/538/548/52
abdominal painGastrointestinal disorders2/538/543/52
pyrexiaGeneral disorders5/538/543/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GTx -024GTx-0243 mg of PlaceboTotal
<=18 years0000
Between 18 and 65 years25222471
>=65 years28322888
Age, Continuous
Age, Continuous(years)GTx -024GTx-0243 mg of PlaceboTotal
Mean65.7 ± 10.0366.3 ± 10.5165.6 ± 8.7365.9 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)GTx -024GTx-0243 mg of PlaceboTotal
Female19201756
Male343435103
Region of Enrollment
Region of Enrollment(participants)GTx -024GTx-0243 mg of PlaceboTotal
United States393736112
Argentina14171647
08

Study locations

52 sites
  • Alaska Cancer Research and Education Center
    Anchorage, Alaska 99508, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Compassionate Cancer Care
    Corona, California 92882, United States
  • Compassionate Cancer Care Medical Group
    Fountain Valley, California 92708, United States
  • Pacific Coast Hematology/Oncology Medical Group, Inc.
    Fountain Valley, California 92708, United States
  • Desert Hematology Oncology Medical Group
    Rancho Mirage, California 92270, United States
  • Compassionate Cancer Care
    Riverside, California 92501, United States
  • Penrose Cancer Center
    Colorado Springs, Colorado 80907, United States
  • Dorcy Cancer Center
    Pueblo, Colorado 81004, United States
  • Hartford Hospital Cancer Clinical Research Office
    Hartford, Connecticut 06102, United States
  • Medical Oncology & Hematology, PC
    Waterbury, Connecticut 06708, United States
  • Gainesville Hematology Oncology Associates
    Gainesville, Florida 32605, United States
  • Horizon Institute for Clinical Research
    Hollywood, Florida 33021, United States
  • Hematology Oncology Associates
    Lake Worth, Florida 33461, United States
  • The Radiation Oncology Group
    Lake Worth, Florida 33461, United States
  • Watson Clinic LLP, Center for Cancer Care & Research
    Lakeland, Florida 33805, United States
  • Osler Medical
    Melbourne, Florida 32901, United States
  • Innovative Medical Research of South Florida, Inc.
    Miami, Florida 33179, United States
  • Florida Medical Clinic, PA
    Zephyrhills, Florida 33542, United States
  • Augusta Oncology Associates
    Augusta, Georgia 30901, United States
  • Dublin Hematology and Oncology
    Dublin, Georgia 31021, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Kentuckiana Cancer Institute
    Louisville, Kentucky 40202, United States
  • Johns Hopkins University Clinical Trial Unit
    Baltimore, Maryland 21287, United States
  • Center for Cancer & Blood Disorders
    Bethesda, Maryland 20817, United States
  • The Center for Clinical Research WA County Hospital
    Hagerstown, Maryland 21740, United States
  • Newland Medical Center
    Southfield, Michigan 48075, United States
  • The West Clinic
    Corinth, Mississippi 38834, United States
  • West Clinic
    Corinth, Mississippi 38834, United States
  • The West Clinic
    Southaven, Mississippi 38671, United States
  • West Clinic
    Southaven, Mississippi 38671, United States
  • Hematology & Oncology Associates at Bridgeport
    Tupelo, Mississippi 38801, United States
  • Heartland Hematology-Oncology Associates
    Kansas City, Missouri 64118, United States
  • Donald H. Berdeaux, MD, FACP, PC
    Great Falls, Montana 59405, United States
  • Great Falls Clinic, LLP - Clinic Cancer Care
    Great Falls, Montana 59405, United States
  • Creighton University Hematology/Oncology Clinic
    Omaha, Nebraska 68131, United States
  • Cancer Care of Western North Carolina
    Ashville, North Carolina 28801, United States
  • Four Seasons Hospice & Palliative Care
    Flat Rock, North Carolina 28731, United States
  • Hanover Medical Specialists
    Wilmington, North Carolina 28401, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Hematology Oncology Consultants
    Worthington, Ohio 43235, United States
  • Consultants in Medical Oncology and Hematology
    Drexel Hill, Pennsylvania 19026, United States
  • Urological Associates of Lancaster
    Lancaster, Pennsylvania 17604, United States
  • Berks Hematology-Oncology Associates
    West Reading, Pennsylvania 19611, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29403, United States
  • West Clinic
    Memphis, Tennessee 38104, United States
  • West Clinic
    Memphis, Tennessee 38120, United States
  • Dallas Oncology Consultants
    Dallas, Texas 75237, United States
  • Providence Everett Medical Center, Cancer Research Department
    Everett, Washington 98201, United States
  • University of Alberta Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Publications

  • Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013 Apr;14(4):335-45. doi: 10.1016/S1470-2045(13)70055-X. Epub 2013 Mar 14. PubMed 23499390 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2007
First posted
May 1, 2007
Start
May 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Feb 21, 2013
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00467844
Lead sponsor
GTx
Responsible party
Sponsor
First posted
May 1, 2007
Start date
May 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Feb 21, 2013
Last update
Jul 11, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion